Needham & Company Upgrades Pacira Pharmaceuticals (PCRX) to Buy; 'All Signs Point to a Significant Exparel Growth Inflection'
Tweet Send to a Friend
Needham & Company upgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Hold to Buy with a price target of $54.00.Analsyt Serge Belanger ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
